Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (181-190 of 752) with videos related to

Pageof 76
Sort By:
International Journal of Cardiology|October 9, 2012
Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillationMatthias K Freynhofer, Susanne C Gruber, Veronika Bruno, et al.
American Heart Journal|December 24, 2003
Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarctionMariann Gyöngyösi, Dietmar Glogar, Franz Weidinger, et al.
Journal of Cellular and Molecular Medicine|February 21, 2009
Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-betaRudolf Jarai, Christoph Kaun, Thomas W Weiss, et al.
Thrombosis and Haemostasis|September 19, 2014
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?Jolanta M Siller-Matula, Dietmar Trenk, Karsten Schrör, et al.
International Journal of Cardiology|May 18, 2023
European practice patterns for antiplatelet management in NSTE-ACS patients: Results from the REal-world ADoption survey focus on Acute antiPlatelet Treatment (READAPT) surveyDominick J Angiolillo, David Erlinge, José Luis Ferreiro, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 7, 2026
Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failureHeinz Drexel, Matthias Frick, Andreas Zirlik, et al.
Thrombosis and Haemostasis|October 14, 2010
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantationIoannis Tentzeris, Rudolf Jarai, Serdar Farhan, et al.
Thrombosis and Haemostasis|December 8, 2010
Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillationMatthias K Freynhofer, Veronika Bruno, Rudolf Jarai, et al.
Thrombosis Research|March 12, 2004
The E-selectin S128R polymorphism is not a risk factor for coronary artery disease in patients with diabetes mellitus type 2Georg Endler, Markus Exner, Marianne Raith, et al.
Thrombosis and Haemostasis|May 6, 2011
Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thrombosesMatthias K Freynhofer, Veronika Bruno, Ivan Brozovic, et al.
Pageof 76

Showing results (181-190 of 752) with videos related to

Sort By:
Pageof 76
International Journal of Cardiology|October 9, 2012
Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillationMatthias K Freynhofer, Susanne C Gruber, Veronika Bruno, et al.
American Heart Journal|December 24, 2003
Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarctionMariann Gyöngyösi, Dietmar Glogar, Franz Weidinger, et al.
Journal of Cellular and Molecular Medicine|February 21, 2009
Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-betaRudolf Jarai, Christoph Kaun, Thomas W Weiss, et al.
Thrombosis and Haemostasis|September 19, 2014
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?Jolanta M Siller-Matula, Dietmar Trenk, Karsten Schrör, et al.
International Journal of Cardiology|May 18, 2023
European practice patterns for antiplatelet management in NSTE-ACS patients: Results from the REal-world ADoption survey focus on Acute antiPlatelet Treatment (READAPT) surveyDominick J Angiolillo, David Erlinge, José Luis Ferreiro, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 7, 2026
Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failureHeinz Drexel, Matthias Frick, Andreas Zirlik, et al.
Thrombosis and Haemostasis|October 14, 2010
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantationIoannis Tentzeris, Rudolf Jarai, Serdar Farhan, et al.
Thrombosis and Haemostasis|December 8, 2010
Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillationMatthias K Freynhofer, Veronika Bruno, Rudolf Jarai, et al.
Thrombosis Research|March 12, 2004
The E-selectin S128R polymorphism is not a risk factor for coronary artery disease in patients with diabetes mellitus type 2Georg Endler, Markus Exner, Marianne Raith, et al.
Thrombosis and Haemostasis|May 6, 2011
Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thrombosesMatthias K Freynhofer, Veronika Bruno, Ivan Brozovic, et al.
Pageof 76